Page 6,558«..1020..6,5576,5586,5596,560..6,5706,580..»

Allstate Sues Florida Neurologic Clinic for $7.6M in False Claims

Posted: Published on August 31st, 2012

A Florida neurologic clinic that specializes in treating patients with traumatic brain and spinal cord injuries is being sued by a major automotive insurance company for more than $7 million in false claims stemming from charges it abused patients, failed to provide treatment, and kept them hospitalized without medical justification. Allstate Insurance Co. has filed suit against the Florida Institute for Neurologic Rehabilitation, Inc., and its owner, Joseph Brennick, in the U.S. District Court for Middle District of Florida under the federal Racketeer Influence and Corrupt Act, for breach of contract, and a variety of fraud charges. At stake, $7.6 million in allegedly false medical payments for injured drivers insured by Allstate in the state of Michigan. The Wauchula, Fla.-based FINR advertises itself as the leader in treating traumatic brain injuries, neurorehabilitation, neuropsychiatric disorders, and spinal cord injuries. Its basic services include offering occupational speech physical therapy, and counseling to help injured drivers make the transition from the hospital to their homes. Although FINR is located in Florida, its largest contingent of patients came from Michigan, where the company has carried out an aggressive and extensive marketing campaign using online resources, circulating print advertising materials, making presentations at conferences, and … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Allstate Sues Florida Neurologic Clinic for $7.6M in False Claims

StemCells, Inc. to Announce Interim Data on Spinal Cord Injury Trial at the 2012 Annual Scientific Meeting of the …

Posted: Published on August 31st, 2012

NEWARK, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that Armin Curt, MD, Professor and Chairman of the Spinal Cord Injury Center at Balgrist University Hospital, University of Zurich, and principal investigator for the Company's Phase I/II clinical trial in chronic spinal cord injury, will make an oral presentation on the progress of the trial on Monday, September 3 at the 51st Annual Scientific Meeting of the International Spinal Cord Society (ISCOS), which is being held in London, England, on September 3-5, 2012. In his presentation, Dr. Curt will present six-month interim data from the first patient cohort in the trial. The three patients in the first cohort all have thoracic (chest-level) spinal cord injury classified as AIS A, in which there is no neurological function below the injury level. The second and third cohorts will be patients classified as AIS B and AIS C, those with less severe injury, in which there is some preservation of sensory or motor function. In addition to assessing safety, the trial will assess preliminary efficacy based on defined clinical endpoints, such as changes in sensation, motor function and bowel/bladder function. The trial is being conducted at Balgrist University Hospital, … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on StemCells, Inc. to Announce Interim Data on Spinal Cord Injury Trial at the 2012 Annual Scientific Meeting of the …

McKillop on track for Paralympics double

Posted: Published on August 31st, 2012

By John Haughey BBC Sport NI Michael McKillop will aim to extend a six-year unbeaten record at Paralympic level when he defends his 800m T37 title in the Olympic Stadium on Saturday evening. It could be a very special night of action for Northern Ireland athletes with Jason Smyth and Sally Brown also both set to race for track and field medals. McKillop heads into the Games hoping to clinch double gold as he will also compete in the T37 1500m final on Monday evening. The 22-year-old Team Ireland athlete has not lost in paralympic events since taking silver in the 1500m in the 2006 World Championships. The Glengormley native responded by winning the World 800m title in Holland a couple of days later and an unbroken run of wins since then includes his gold medal in Beijing. Michael's mild from of cerebral palsy was discovered by doctors when he was two years old. "I was brought to hospital after I fell down the stairs and it was then my parents were told," says the paralympic star, who is coached by his father Paddy. "My parents took it in their stride and got me the best treatment. They did sport … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on McKillop on track for Paralympics double

CORRECTING and REPLACING Pate Rehabilitation Joins Forces with Fort Worth Safe Communities Coalition to Educate Local …

Posted: Published on August 31st, 2012

Local brain injury rehabilitation center and Fort Worth community come together to prevent brain injuries among local elementary, middle and high school students CORRECTION...by Pate Rehabilitation DALLAS--(BUSINESS WIRE)--Second graph of release dated August 28, 2012 should read: Fort Worth Safe Communities Coalition along with Fort Worth police and firefighters will be handing out donated helmets on Wednesday, Sept. 12 at pre-selected elementary, middle and high schools to students who arrive on their bicycles, skateboards or scooters without any head protection. Pate Rehabilitation will be on-site at Forest Oak Middle School helping hand out helmets. (Sted: Pate will be handing out their donated helmets on Friday, August 31, at Forest Oak Middle School to students who arrive on their bicycles, skateboards or scooters without any head protection.) Brain injuries can be a life altering event that no one wants to see anyone go through, especially children. While there has been great improvement in the treatment of brain injuries, prevention will always outweigh the cure. The corrected release reads: PATE REHABILITATION JOINS FORCES WITH FORT WORTH SAFE COMMUNITIES COALITION TO EDUCATE LOCAL YOUTH ON BICYCLE HELMET SAFETY Local brain injury rehabilitation center and Fort Worth community come together to prevent brain injuries … Continue reading →

Posted in Brain Injury Treatment | Comments Off on CORRECTING and REPLACING Pate Rehabilitation Joins Forces with Fort Worth Safe Communities Coalition to Educate Local …

Nanoparticle Offers Early-Stage Treatment to Brain Injuries

Posted: Published on August 31st, 2012

Researchers at Rice University are reporting success in using a nanoparticle as an emergency treatment for traumatic brain injuries.The research could also improve brain injury treatment for stroke victims and organ transplant patients. The nanoparticle, which was developed at Rice University, is polyethylene glycol-hydrophilic carbon clusters (PEG-HCC). It's already being tested in cancer treatment, where it has shown itself to be a powerful antioxidant. In the current research, the Rice team took PEG-HCCs effectiveness as an antioxidant one step further, by using it to counter something called reactive oxygen species (ROS)after a traumatic brain injury, cells release an excessive amount of an ROS called superoxide (SO) into the blood. The research, which was published in the journal ACS Nano (Antioxidant Carbon Particles Improve Cerebrovascular Dysfunction Following Traumatic Brain Injury), found that PEG-HCC provides a balance to the blood counteracting the effects of the SO when the bodys natural enzymes become overwhelmed by the ROS. Superoxide is the most deleterious of the reactive oxygen species, as its the progenitor of many of the others, says James Tour, Rice chemist and a co-author of the paper, in the university press release covering the research.If you dont deal with SO, it forms peroxynitrite … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Nanoparticle Offers Early-Stage Treatment to Brain Injuries

Santhera Reports Stable Product Sales and Substantially Reduced Expenses and in First Half Year of 2012

Posted: Published on August 31st, 2012

Liestal, Switzerland, August31, 2012 - Santhera Pharmaceuticals (SIX:SANN) announced today the financial results for the first half of 2012. In the first six months of 2012, Catenagenerated net sales of CHF1.7 million. The net cash burn was significantly reduced to CHF7.2 million resulting in a net loss of CHF5.5 million. As of June30, 2012, Santhera had cash reserves of CHF16.2 million, which secure the funding of the current operations into 2013 and well beyond the expected decision by the European Medicines Agency (EMA) on the Marketing Authorization Application (MAA) in Leber`s Hereditary Optic Neuropathy (LHON). Main achievements in 2012: Stable Catenasales in Canada and through named patient and special access programs in Europe and other territories Preparations for product commercialization in LHON in Europe following potential approval by the EMA Key financial figures (unaudited) 1 as of December31, 2011 Commenting on the operational and financial performance in the first six months of 2012, Thomas Meier, Chief Executive Officer of Santhera, said, "In the first six months of 2012, we have focused on the regulatory approval process and prepared for product commercialization in LHON. During this period we also achieved substantial cost reductions, which resulted in a markedly reduced cash burn … Continue reading →

Comments Off on Santhera Reports Stable Product Sales and Substantially Reduced Expenses and in First Half Year of 2012

Million Women Study Supports Correlation between Hormone Replacement Therapy in Treating Menopause Symptoms and Cancer

Posted: Published on August 31st, 2012

BEVERLY HILLS, Calif., Aug. 30, 2012 /PRNewswire/ -- The Million Women Study is a study, conducted by UK researchers, of women's health analyzing data from more than one million women aged 50 and over. It is a collaborative project between Cancer Research UK and the National Health Service (NHS), with additional funding from the Medical Research Council (UK). The study has abundantly fulfilled its aims of illuminating the answers to crucial questions about factors affecting the health of women in this age group as its collaborators continue their frequent contributions to prestigious medical journals of what has become an impressive series of landmark medical papers. Eaton Scientific Systems, Ltd. CEO, Michael Borkowski, says that "the Million Women Study, is both alarming and important to the need for non-hormonal treatments like Eaton's Tropine 3 in dealing with pre-menopause, menopause and peri-menopause symptoms affecting millions of women in the US and around the world who do not want to risk using hormonal treatments because of their potential relationship with cancer." One key focus of the study relates to the effects of hormone replacement therapy use on women's health. The study has confirmed the findings in the Women's Health Initiative (WHI) that women … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Million Women Study Supports Correlation between Hormone Replacement Therapy in Treating Menopause Symptoms and Cancer

Dr. Andrew L. Kung Named Director of Pediatric Hematology, Oncology and Stem Cell Transplantation at NewYork …

Posted: Published on August 31st, 2012

Research Program Will Focus on Developing the Next Generation of Pediatric Hematology and Cancer Treatments Newswise NEW YORK (August 27, 2012) - Dr. Andrew L. Kung has joined the Department of Pediatrics at New York-Presbyterian Morgan Stanley Children's Hospital/Columbia University Medical Center as director of the Division of Pediatric Hematology Oncology and Stem Cell Transplantation. In this role he will oversee clinical care and develop a research program aimed at harnessing the next generation of therapies for cancer and blood disorders in pediatric patients. "I am pleased to welcome Dr. Kung, who is an exceptional clinician and renowned worldwide for his basic and translational oncology research," says Dr. Lawrence Stanberry, pediatricianin-chief at New York-Presbyterian Morgan Stanley Children's Hospital/Columbia University Medical Center and the Rueben S. Carpentier Professor and Chairman of the Department of Pediatrics at Columbia University College of Physicians and Surgeons. "Dr. Kung's ambitious plan to launch a comprehensive program designed to tailor treatments to individual patients and speed the development of new pediatric therapies will further establish New York-Presbyterian/Columbia University Medical Center as a preeminent leader in cancer research. The entire cancer research community at the medical center is thrilled to welcome Dr. Kung to our ranks," says … Continue reading →

Posted in Stem Cell Research | Comments Off on Dr. Andrew L. Kung Named Director of Pediatric Hematology, Oncology and Stem Cell Transplantation at NewYork …

Hamilton Thorne Announces 2012 Second Quarter Financial Results

Posted: Published on August 31st, 2012

BEVERLY, MA and TORONTO--(Marketwire -08/30/12)- Hamilton Thorne Ltd. (HTL.V), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today reported operational and financial results for the second quarter and six months year-to-date ended June 30, 2012. "During the second quarter of 2012, Hamilton Thorne sales declined versus the prior year, interrupting the trend of nine consecutive quarters of year-over-year growth. Laser sales were down slightly, while CASA sales were off substantially, due in part to cyclical fluctuations in demand, particularly for toxicology products, and due in part to purchase deferrals in anticipation of new product announcements," said David Wolf, President and Chief Executive Officer of Hamilton Thorne Ltd. "While our year-to-date sales decline was disappointing, we expect to see a return to steady growth as the demand for new products such as our LYKOS and XYRCOS lasers continues to grow, as the refreshed CASA product line roll-out proceeds, and as our new IMSI-Strict software captures market share." Mr. Wolf continued, "In order to utilize our resources more effectively, we have reduced our R&D and marketing spending in new market development and have refocused our resources on penetrating … Continue reading →

Posted in Stem Cell Research | Comments Off on Hamilton Thorne Announces 2012 Second Quarter Financial Results

International Stem Cell Corp to Participate in Upcoming Investor Conferences

Posted: Published on August 31st, 2012

CARLSBAD, CA--(Marketwire -08/30/12)- International Stem Cell Corporation (ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, today announced that the Company will attend and present at the following investor conferences in September. Wall Street Analyst Forum Investor ConferenceDate: Friday, September 7, 2012 Time: 10:35 am ET Location: Omni Parker House - Boston, MA Rodman & Renshaw Annual Global Investment ConferenceDate: Monday, September 10, 2012 Time: 11:40 am ET Location: The Waldorf Astoria Hotel, New York, NY Please contact the conference organizers if you have an interest in attending these conferences or if you would like to arrange a meeting with International Stem Cell's management team. You may also contact Mark McPartland with MZ Group via email markmcp@mzgroup.us or phone 1-212-301-7130 to arrange a meeting with management. Additional information of the investor presentations will be available on the investor relations section of the Company's website http://www.internationalstemcell.com. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes … Continue reading →

Posted in Stem Cell Research | Comments Off on International Stem Cell Corp to Participate in Upcoming Investor Conferences

Page 6,558«..1020..6,5576,5586,5596,560..6,5706,580..»